Stockscreener 앱 받기
5.60
1.23%
-0.07
시간 외 거래:
5.58
-0.02
-0.36%
전일 마감가:
$5.67
열려 있는:
$5.73
하루 거래량:
2.73M
Relative Volume:
0.72
시가총액:
$1.72B
수익:
$248.37M
순이익/손실:
$11.74M
주가수익비율:
112.00
EPS:
0.05
순현금흐름:
$18.24M
1주 성능:
-3.28%
1개월 성능:
+0.18%
6개월 성능:
+54.70%
1년 성능:
-15.15%
1일 변동 폭
$5.575
$5.73
1주일 범위
$5.555
$5.82
52주 변동 폭
$3.3812
$6.67
맨카인드 Stock (MNKD) Company Profile
명칭
Mannkind Corp
전화
818-661-5000
주소
1 CASPER STREET, DANBURY, CA
MNKD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
5.60 | 1.74B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
맨카인드 Stock (MNKD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-13 | 개시 | Leerink Partners | Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-10-10 | 개시 | Leerink Partners | Outperform |
| 2025-07-16 | 재개 | H.C. Wainwright | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-10 | 개시 | Wedbush | Outperform |
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-12-19 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-10-10 | 개시 | Wedbush | Outperform |
| 2021-05-14 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | 개시 | Oppenheimer | Outperform |
| 2019-10-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-05-14 | 개시 | BTIG Research | Buy |
| 2019-03-04 | 개시 | SVB Leerink | Outperform |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2018-02-28 | 다운그레이드 | Maxim Group | Hold → Sell |
| 2017-11-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2017-10-10 | 개시 | H.C. Wainwright | Buy |
| 2017-10-06 | 재확인 | Maxim Group | Buy |
| 2017-08-11 | 개시 | Maxim Group | Buy |
| 2016-05-10 | 재확인 | Piper Jaffray | Underweight |
| 2016-05-10 | 재확인 | RBC Capital Mkts | Underperform |
| 2016-01-06 | 재확인 | Piper Jaffray | Underweight |
| 2016-01-06 | 재확인 | RBC Capital Mkts | Underperform |
| 2015-11-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | 다운그레이드 | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | 재확인 | RBC Capital Mkts | Outperform |
| 2015-05-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2015-05-11 | 재확인 | MLV & Co | Hold |
| 2015-04-16 | 재확인 | RBC Capital Mkts | Outperform |
모두보기
맨카인드 주식(MNKD)의 최신 뉴스
MannKind Corp Is Suddenly Everywhere – Is MNKD the Next Sleeper Stock You’ll Regret Ignoring? - AD HOC NEWS
MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care - Finviz
12 Best NASDAQ Stocks to Buy in 2026 - Insider Monkey
MannKind (MNKD) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
MNKD (MannKind) ROCE % : 17.64% (As of Sep. 2025) - GuruFocus
Even though MannKind (NASDAQ:MNKD) has lost US$61m market cap in last 7 days, shareholders are still up 80% over 5 years - Yahoo Finance
How Pediatric FUROSCIX Expansion And New Patents At MannKind (MNKD) Has Changed Its Investment Story - simplywall.st
MannKind Stock Slips Despite FDA Clearing Pediatric Use Of Heart Failure Drug — What’s Spooking Investors? - Stocktwits
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? - Yahoo Finance
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? - The Motley Fool
MannKind stock slips despite FDA clearing pediatric use of heart failure drug — what’s spooking investors? - MSN
FDA approves FUROSCIX for pediatric patients weighing 43kg or more By Investing.com - Investing.com South Africa
FDA approves FUROSCIX for pediatric patients weighing 43kg or more - Investing.com
MannKind Corporation Announces FDA Approval of FUROSCIX® for Pediatric Use and Patent Issuance for FUROSCIX ReadyFlow™ Autoinjector - Quiver Quantitative
Shot for fluid buildup could help kids and work at home in 10 seconds - Stock Titan
Can MannKind Corporation stock hit record highs again2025 Valuation Update & Consistent Growth Stock Picks - ulpravda.ru
Michael Castagna Sells 65,804 Shares of MannKind (NASDAQ:MNKD) Stock - MarketBeat
Insider Sell: Michael Castagna Sells 65,804 Shares of MannKind C - GuruFocus
Is MannKind Corporation stock affected by interest rate hikesMarket Movement Recap & Reliable Intraday Trade Alerts - DonanımHaber
How MannKind Corporation stock performs in weak economyMarket Growth Report & Weekly Top Gainers Alerts - Улправда
Insider Sell: Michael Castagna Sells 42,116 Shares of MannKind C - GuruFocus
MannKind Corporation (NASDAQ:MNKD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
MannKind (NASDAQ: MNKD) adds audited and pro forma scPharma results to merger filing - Stock Titan
MannKind (MNKD): Evaluating Valuation After FDA Acceptance of the FUROSCIX ReadyFlow Autoinjector sNDA - simplywall.st
Short Squeeze: Will SHPH stock gain from lower inflation2025 Market WrapUp & Free Weekly Watchlist of Top Performers - moha.gov.vn
The Bull Case For MannKind (MNKD) Could Change Following FDA Review Of FUROSCIX ReadyFlow Autoinjector - simplywall.st
MannKind stock price target raised to $9 by Leerink on Tyvaso DPI royalties - Investing.com
MannKind (NASDAQ:MNKD) CEO Michael Castagna Sells 107,920 Shares of Stock - MarketBeat
MannKind (MNKD) Valuation Check After FDA Filing Progress for FUROSCIX ReadyFlow Autoinjector - simplywall.st
Mannkind EVP Thomson sells $823k in shares By Investing.com - Investing.com South Africa
Insider Selling: Michael Castagna Sells Shares of MannKind Corp (MNKD) - GuruFocus
MNKD FinancialsIncome Statement - Quiver Quantitative
Mannkind EVP Thomson sells $823k in shares - Investing.com
Mannkind CEO Castagna sells $601k in shares By Investing.com - Investing.com UK
Mannkind CEO Castagna sells $601k in shares - Investing.com
MannKind Corp Executives Sell Shares - TradingView — Track All Markets
VP Thomson Sells 147,780 ($823.1K) Of MannKind Corp [MNKD] - TradingView
Is MannKind Corporation (NNFN) stock undervalued after correctionWeekly Investment Report & Growth Focused Stock Reports - Newser
How MannKind Corporation (NNFN) stock moves in volatile trading sessionsJuly 2025 EndofMonth & Weekly Momentum Stock Picks - Newser
MannKind's ReadyFlow Autoinjector: A Game Changer For Heart Failure Patients (NASDAQ:MNKD) - Seeking Alpha
Is There Now an Opportunity in MannKind After This Year’s Share Price Pullback? - Yahoo Finance
MAI Capital Management Reduces Stock Holdings in MannKind Corporation $MNKD - MarketBeat
Can MannKind Corporation (NNFN) stock attract analyst upgradesQuarterly Profit Report & AI Based Buy and Sell Signals - Newser
Can MannKind Corporation (NNFN) stock sustain double digit ROEMarket Movement Recap & Long Hold Capital Preservation Plans - Newser
FDA Reviewing 10-Second Treatment for Edema in Heart Failure - Diagnostic and Interventional Cardiology
MannKind (MNKD) Awaits FDA Decision on Furoscix Autoinjector - GuruFocus
FDA accepts MannKind’s sNDA for ReadyFlow Autoinjector - Investing.com
MannKind (MNKD) Awaits FDA Decision on FUROSCIX ReadyFlow Autoin - GuruFocus
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease - The Manila Times
MannKind Corporation Announces FDA Acceptance of sNDA for FUROSCIX ReadyFlow™ Autoinjector, Targeting Improved Management of Chronic Heart Failure and Kidney Disease - Quiver Quantitative
MannKind (Nasdaq: MNKD) lands FDA sNDA review, PDUFA July 26, 2026 for ReadyFlow - Stock Titan
맨카인드 (MNKD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):